Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

sanyko d.o.o., zagreb - adhezivna sredstva za zaustavljanje krvarenja pri kirurškim zahvatima

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

mediva d.o.o., zagreb - laringealna maska za osiguravanje pristupa dišnim putevima i funkcionalno odvajanje respiratornog i digestivnog trakta

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

bontech research co. d.o.o., split - slušna pomagala

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

octapharma (ip) sprl, researchdreef 65, brussels (anderlecht), belgija - imunoglobulin normalni, ljudski - otopina za injekciju - 165 mg/ml - urbroj: jedan ml otopine sadrži: imunoglobulin normalni ljudski 165 mg (čistoće od najmanje 95% igg)

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

dopharma research b.v., zalmweg 24, 4941 vx raamsdonksveer, nizozemska - deksametazon (u obliku natrijevog deksametazonfosfata) - otopina za injekciju - kortikosteroidi za sustavnu primjenu, deksametazon - goveda, konja, svinja, pasa, mačaka

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

dopharma research b.v., zalmweg 24, 4941 vx raamsdonksveer, nizozemska - trimetoprim; sulfametoksazol - otopina za primjenu u vodi za piće - antibakterijski pripravci za sustavne infekcije - svinja (tovne svinje), kokoši (tovni pilići)

Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

dopharma research b.v., zalmweg 24, 4941 vx raamsdonksveer, nizozemska - tilozin - granule za primjenu u vodi za piće/mlijeku - antibakterijski vmp za sustavne infekcije - goveda (teladi), svinja, kokoši, purana

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artritis, reumatoidni - imunosupresivi - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Europska Unija - hrvatski - EMA (European Medicines Agency)

bial portela & companhia s.a. - opicapone - parkinsonova bolest - antiparkinsonski lijekovi - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Europska Unija - hrvatski - EMA (European Medicines Agency)

immedica pharma ab - phenylbutyrate natrija - ornithine carbamoyltransferase deficiency disease; citrullinemia; carbamoyl-phosphate synthase i deficiency disease - drugi gastrointestinalni trakt i metabolizam, lijekovi, - Аммонапс prikazan kao dodatna terapija kod kroničnih poremećaja ciklusa ureje, uključujući nedostatke синтетазы carbamylphosphate, transcarbamylase синтетазы orargininosuccinate ornitin . ona je prikazana svim pacijentima sa prezentacijom novorođenčadi-početak (potpuni nedostatak enzima, predstavljajući u prvih 28 dana života). slavi se i u bolesnika s kasnim početkom bolesti(djelomični nedostatak enzima, predstavljajući nakon prvog mjeseca života), koje imaju povijest hyperammonaemic wernicke.